Related Experiment Video

Updated: Jun 27, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Arkadiusz Z Dudek1, Jakub Zolnierek, Anu Dham

  • 1Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA. dudek002@umn.edu

Cancer
|December 4, 2008
PubMed
Abstract

Insights

Sequential treatment with sorafenib then sunitinib demonstrated superior disease control in advanced renal cell carcinoma patients compared to sunitinib then sorafenib. Further investigation is warranted for this treatment sequence.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) used for advanced renal cell carcinoma.
  • Sequential TKI therapy is an emerging treatment strategy.

Purpose of the Study:

  • To evaluate the efficacy of sequential sunitinib and sorafenib treatment in advanced renal cell carcinoma.
  • To compare the outcomes of sorafenib followed by sunitinib versus sunitinib followed by sorafenib.

Main Methods:

  • Retrospective study of 49 advanced renal cell carcinoma patients.
  • Patients received either sorafenib then sunitinib (Group A) or sunitinib then sorafenib (Group B).
  • Tumor response assessed by RECIST criteria; toxicity and survival data collected.

Main Results:

  • Group A (sorafenib-sunitinib) had longer median stable disease duration (20 weeks) and time to progression (78 weeks) than Group B (sunitinib-sorafenib).
  • Multivariate analysis showed Group B had a significantly shorter time to progression (RR 3.0; P=.016).
  • Median overall survival was longer in Group A (102 weeks) versus Group B (45 weeks), though not statistically significant (P=.061).

Conclusions:

  • Sequential treatment with sorafenib followed by sunitinib resulted in longer disease control.
  • This sequence warrants further investigation for advanced renal cell carcinoma management.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...